On March 29, 2026, Connect Biopharma Holdings Ltd entered into a securities purchase agreement to sell 6,130,000 shares at $3.25 each, raising approximately $20.2 million to fund its product development and operations into late 2027. The placement is set to close on March 31, 2026, and is exempt from SEC registration requirements.